Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients

Binus, A.M.; Qureshi, Abrar A.; Li, V.W.; Winterfield, Laura

doi:10.1111/j.1365-2133.2011.10565.x

Cited by 335 publications

(426 citation statements)

References 28 publications

Supporting

Mentioning

330

Contrasting

Unclassified

Order By: Relevance

“…3,6,9 O tratamento de primeira escolha é descrito com corticoterapia sistêmica em dose imunossupressora, opção com mais evidências e sucesso terapêutico relatados, sendo também a opção preferencial em crianças. 10,12 Os resultados são rápidos, com melhora das lesões em dias a semanas, o que corrobora com a resposta satisfatória apresentada no nosso caso.…”

Section: Discussionunclassified

Pioderma Gangrenoso em Lactente

Martins

Mattos

Abinader

et al. 2016

SPDV

View full text Add to dashboard Cite

RESUMO -Pioderma gangrenoso é uma dermatose cutânea incomum, de patogênese desconhecida, incluída no grupo das dermatoses neutrofílicas. Caracteriza-se como ulceração não infecciosa, necrotizante e dolorosa da pele. Acomete preferencialmente adultos, sendo raro em crianças (menos de 4%) e com poucos casos relatados na literatura de acometimento na faixa etária <1 ano. O diagnóstico geralmente é baseado em evidências clínicas e confirmado com a exclusão das outras etiologias de lesões ulceradas cutâneas. Relatamos um caso de pioderma gangrenoso em uma lactente de 4 meses de idade, com lesões ulceradas múltiplas na região de nádegas, sem comprometimento sistêmico e com resposta satisfatória e efetiva ao tratamento com corticoterapia oral. PALAVRAS-CHAVE -Pioderma Gangrenoso; Lactente. 1 Fagedenismo crónico, dermatite gangrenosa e pioderma fagedênico são termos sinônimos com valor histórico para o pioderma gangrenoso, que é definido como uma doença inflamatória e neutrofílica, não infecciosa, que geralmente evolui para ulcerações cutâneas e comprometimento sistémico, estando associada ao fenômeno patérgico em até 30% dos casos e a doenças sistêmicas em 30-70% dos casos, sendo principalmente associada à doença de Crohn, retocolite ulcerativa, artrite reumatóide e doenças hematológicas. Pyoderma Gangrenosum in an Infant ABSTRACT -Pyoderma gangrenosum is an uncommon cutaneous dermatosis of unknown pathogenesis, included in the group1,2,6 O PG é considerado idiopático em 25-50% dos casos.3 Estima-se que sua incidência ocorra entre 3 a 10 casos por milhão de pessoas/ano, 1 sendo mais frequente em adultos e considerada muito rara na infância, principalmente quando considerada a faixa etária < 1 ano. 4A etiologia e patogênese do PG permanecem desconhecidas, apesar dos avanços científicos na compreensão da

show abstract

Section: Discussionunclassified

Pioderma Gangrenoso em Lactente

Martins

Mattos

Abinader

et al. 2016

SPDV

View full text Add to dashboard Cite

show abstract

“…Treatment response of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort observational study Introduction Pyoderma gangrenosum is a rare, painful ulcerative inflammatory dermatosis that is associated with considerable morbidity 728,749 and a reported threefold increased risk of death. 729 Given that mortality in PG exceeds that of underlying comorbid disease, it may be inferred that the disease itself and/or the therapeutic interventions used for its treatment are responsible for the increased risk of death in affected patients.…”

Section: Clinical Conclusionmentioning

confidence: 99%

“…728 A 2012 retrospective cohort study in the UK has reported an adjusted incidence rate (standardised to the European standard population) of 0.63 per 100,000 person-years. 729 The development of PG was associated with a threefold increased risk of death compared with general population controls, and a 72% increased mortality over controls with IBD.…”

Section: Introductionmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

“…The most common presentation of PG is an inflammatory papule or pustule that progresses to a painful ulcer with a violaceous undermined border and a purulent base. More than 50% of patients with PG have an associated systemic disease, most commonly inflammatory bowel disease (14-34%), arthropathies (11-25%) and hematologic disease or hematologic malignancy (20%) [1]. Systemic lupus erythematosus (SLE) is not a commonly recognized associate of PG.…”

Section: Introductionmentioning

confidence: 99%

Pyoderma Gangrenosum in a Patient With Systemic Lupus Erythematosus: Case Report

Hania

2014

J Med Cases

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a rare and unusual manifestation of systemic lupus erythematosus (SLE). It deserves special mention whenever a case of PG is seen in any patient population, due to its rarity. It has an unusual association with SLE, with few documented cases. A case of a 53-year-old male patient, who had an unusual first presentation of SLE in 1995, with mainly hematological and renal manifestations of SLE and with a lack of any dermatological or musculoskeletal features until 2012 is presented here. The patient developed two ulcerating lesions on right leg and was diagnosed with PG following biopsy, which was successfully treated with corticosteroids and appropriate wound management.

show abstract

Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients

Cited by 335 publications

References 28 publications

Pioderma Gangrenoso em Lactente

Pioderma Gangrenoso em Lactente

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Pyoderma Gangrenosum in a Patient With Systemic Lupus Erythematosus: Case Report

Contact Info

Product

Resources

About